- Company
- SK Bioscience & MSD signed a consignment production contract
- by Jung, Sae-Im May 17, 2023 05:38am
- At the contract signing ceremony held in Jongno-gu, Seoul, government officials such as Second Vice Minister of Health and Welfare Park Min-soo, MSD Vice President Sanat Chattopadhyay, Hilleman Research Center CEO Raman Rao, SK Discovery Vice Chairman Choi Chang-won, SK Bioscience President Ahn Jae-yong, Hoon Kim, CEO of Global R&BD, etc. att
- Company
- Duloxetine shows strength in ₩30B antidepressant mkt
- by Nho, Byung Chul May 17, 2023 05:38am
- Last year, top-line sales of the antidepressant duloxetine recorded KRW 17.7 billion, taking a big lead ahead of venlafaxine, which achieved KRW 12.7 billion in sales, and is solidifying its position in the relevant prescription market. According to drug distribution data, sales of duloxetine drugs grew from KRW 15.5 billion to KRW 17.7 b
- Opinion
- [Reporter’s View] Bitter ERPs following spin-offs and sales
- by Eo, Yun-Ho May 17, 2023 05:38am
- The operation of Early Retirement Program (ERP) schemes following sales of business units has been frequenting as an issue in the pharmaceutical industry. Although the spin-off and sales by multinational pharmaceutical companies aim at ‘separation of innovation and legacy, ‘this premise of ‘selecting and focusing’ on its strengths ine
- Company
- Hemophilia drug Hemlibra coverage expansion
- by Chon, Seung-Hyun May 17, 2023 05:37am
- JW Pharmaceutical has laid the foundation for developing Hemlibra, a treatment for hemophilia, into a large-scale product. With the expansion of benefits, treatment benefits are provided to more patients, and expectations for sales growth are rising due to increased prescriptions. According to the Ministry of Health and Welfare on the 16th,
- Policy
- Patent protection for 42 yrs for Humira/32 yrs for Keytruda
- by Lee, Hye-Kyung May 16, 2023 09:07pm
- It was analyzed that Humira maintained its patent protection period for at least 42 years and Keytruda for at least 32 years after filing for material patents with the Evergreening patent strategy. Evergreening refers to extending the term of a patent or extending the term of a patent for more than 20 years in the case of a patent to obtain more
- Company
- Crysvita, the first fast-track drug by Yoon gov, is expected
- by Eo, Yun-Ho May 16, 2023 09:06pm
- It is now possible to prescribe 'Crysvita', the No. 1 rapidly registered drug of the Yoon government. This drug recently passed the Drug Committee (DC) of medical institutions such as SNUH. Kyowa Kirin Korea's (XLH rickets treatment Crysvita is a pediatric treatment that has been clinically proven effective in the field of diseases for whi
- Company
- JAKi Cibinqo owns strengths in dosage adjustments
- by Jung, Sae-Im May 16, 2023 05:40am
- Pfizer's JAK inhibitor ‘Cibinqo (abrocitinib)' has embarked on a full-fledged journey to expand its prescriptions. After landing in major general hospitals at the end of last year, the drug is likely to be registered for reimbursement within the first half of this year. Cibinqo is a Janus kinase 1 (JAK1) inhibitor approved by the Ministry
- Opinion
- [Reporter's view] AI drug development, should face reality
- by Hwang, Jin-joon May 16, 2023 05:39am
- "Artificial intelligence (AI) drug development will be useful, but there is a problem with only talking too much hope. Domestic AI drug development is still at an early stage, so more R&D is needed." These are the words the representative of an AI drug development company attending a recently held event related to digital healthcare threw to
- Company
- Samil, a series of love calls from multinational companies
- by Lee, Seok-Jun May 16, 2023 12:16am
- Samil Pharmaceutical is receiving a series of love calls from multinational companies. This time, it has decided to exclusively distribute and sell all Sandoz products, including the central nervous system (CNS). The CNS division, which was newly established in 2021, will gain momentum for business expansion. It is evaluated that Samil Pharma
- Policy
- Biopharmaceutical CDMO annual average of ↑31%
- by Lee, Hye-Kyung May 15, 2023 05:41am
- Globally, the CDMO market for biopharmaceuticals is growing at an average annual rate of 31%. If this trend continues, the size of the Cell&Gene Therapy CDMO market is expected to reach 10 billion dollars in 2026. Kwon Soon-jae, managing director of ENCell, announced this at the 'CDMO Partnership for Acceleration of Biopharmaceutical Developm
